Eli Lilly and Company $LLY is Draper Asset Management LLC’s 8th Largest Position

Draper Asset Management LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 7.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,768 shares of the company’s stock after selling 284 shares during the period. Eli Lilly and Company makes up approximately 1.9% of Draper Asset Management LLC’s portfolio, making the stock its 8th largest position. Draper Asset Management LLC’s holdings in Eli Lilly and Company were worth $2,922,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Hobbs Wealth Management LLC raised its holdings in Eli Lilly and Company by 0.8% during the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock worth $1,205,000 after purchasing an additional 12 shares in the last quarter. Hixon Zuercher LLC increased its holdings in Eli Lilly and Company by 0.7% in the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock valued at $1,477,000 after buying an additional 12 shares in the last quarter. O Brien Wealth Partners LLC increased its holdings in Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after buying an additional 12 shares in the last quarter. Ascent Capital Management LLC increased its holdings in Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock valued at $409,000 after buying an additional 12 shares in the last quarter. Finally, Willner & Heller LLC increased its holdings in Eli Lilly and Company by 1.5% in the first quarter. Willner & Heller LLC now owns 854 shares of the company’s stock valued at $705,000 after buying an additional 13 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 1.1%

Shares of NYSE LLY opened at $820.97 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The firm’s 50 day moving average price is $765.52 and its 200 day moving average price is $767.43. The firm has a market cap of $777.01 billion, a P/E ratio of 53.66, a price-to-earnings-growth ratio of 1.16 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the business earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Cantor Fitzgerald set a $925.00 target price on shares of Eli Lilly and Company and gave the company an “overweight” rating in a report on Thursday, October 9th. Guggenheim reaffirmed a “buy” rating and issued a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 16th. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Finally, Morgan Stanley lowered their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research report on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $938.61.

Insiders Place Their Bets

In related news, CEO David A. Ricks acquired 1,632 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Daniel Skovronsky acquired 1,000 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.